Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Where will the drugs come from? - PubMed

Affiliations

• PMID: 33529750
• DOI: 10.1016/j.phrs.2021.105465

Free article

Review

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Where will the drugs come from?

Peter L Toogood et al. Pharmacol Res. 2021 Mar.

Free article

Abstract

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic debilitating disease characterized by severe and disabling fatigue that fails to improve with rest; it is commonly accompanied by multifocal pain, as well as sleep disruption, and cognitive dysfunction. Even mild exertion can exacerbate symptoms. The prevalence of ME/CFS in the U.S. is estimated to be 0.5-1.5 % and is higher among females. Viral infection is an established trigger for the onset of ME/CFS symptoms, raising the possibility of an increase in ME/CFS prevalence resulting from the ongoing COVID-19 pandemic. Current treatments are largely palliative and limited to alleviating symptoms and addressing the psychological sequelae associated with long-term disability. While ME/CFS is characterized by broad heterogeneity, common features include immune dysregulation and mitochondrial dysfunction. However, the underlying mechanistic basis of the disease remains poorly understood. Herein, we review the current understanding, diagnosis and treatment of ME/CFS and summarize past clinical studies aimed at identifying effective therapies. We describe the current status of mechanistic studies, including the identification of multiple targets for potential pharmacological intervention, and ongoing efforts towards the discovery of new medicines for ME/CFS treatment.

Keywords: COVID-19; Chronic fatigue syndrome; Drug discovery; Myalgic encephalomyelitis; Systemic exertion intolerance disease.

Similar articles

• Review of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: an evidence-based approach to diagnosis and management by clinicians.

  Bested AC, Marshall LM. Bested AC, et al. Rev Environ Health. 2015;30(4):223-49. doi: 10.1515/reveh-2015-0026. Rev Environ Health. 2015. PMID: 26613325 Review.

• [Post-COVID syndrome with fatigue and exercise intolerance: myalgic encephalomyelitis/chronic fatigue syndrome].

  Renz-Polster H, Scheibenbogen C. Renz-Polster H, et al. Inn Med (Heidelb). 2022 Aug;63(8):830-839. doi: 10.1007/s00108-022-01369-x. Epub 2022 Jul 13. Inn Med (Heidelb). 2022. PMID: 35925074 Free PMC article. Review. German.

• Genetic risk factors for severe and fatigue dominant long COVID and commonalities with ME/CFS identified by combinatorial analysis.

  Taylor K, Pearson M, Das S, Sardell J, Chocian K, Gardner S. Taylor K, et al. J Transl Med. 2023 Nov 1;21(1):775. doi: 10.1186/s12967-023-04588-4. J Transl Med. 2023. PMID: 37915075 Free PMC article.

• Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and COVID-19: is there a connection?

  AlMuhaissen S, Abu Libdeh A, ElKhatib Y, Alshayeb R, Jaara A, Bardaweel SK. AlMuhaissen S, et al. Curr Med Res Opin. 2023 Aug;39(8):1119-1126. doi: 10.1080/03007995.2023.2242244. Epub 2023 Aug 4. Curr Med Res Opin. 2023. PMID: 37501626

• Cardiovascular and haematological pathology in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A role for viruses.

  Nunes JM, Kell DB, Pretorius E. Nunes JM, et al. Blood Rev. 2023 Jul;60:101075. doi: 10.1016/j.blre.2023.101075. Epub 2023 Mar 20. Blood Rev. 2023. PMID: 36963989 Free PMC article. Review.

Cited by

• Shadow Burden of Undiagnosed Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) on Society: Retrospective and Prospective-In Light of COVID-19.

  Araja D, Berkis U, Lunga A, Murovska M. Araja D, et al. J Clin Med. 2021 Jul 6;10(14):3017. doi: 10.3390/jcm10143017. J Clin Med. 2021. PMID: 34300183 Free PMC article.

• Theory: Treatments for Prolonged ICU Patients May Provide New Therapeutic Avenues for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

  Stanculescu D, Larsson L, Bergquist J. Stanculescu D, et al. Front Med (Lausanne). 2021 May 7;8:672370. doi: 10.3389/fmed.2021.672370. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34026797 Free PMC article.

• Exploring the Pathophysiology of Long COVID: The Central Role of Low-Grade Inflammation and Multisystem Involvement.

  Gusev E, Sarapultsev A. Gusev E, et al. Int J Mol Sci. 2024 Jun 9;25(12):6389. doi: 10.3390/ijms25126389. Int J Mol Sci. 2024. PMID: 38928096 Free PMC article. Review.

• Health system support among patients with ME/CFS in Switzerland.

  Tschopp R, König RS, Rejmer P, Paris DH. Tschopp R, et al. J Taibah Univ Med Sci. 2023 Jan 4;18(4):876-885. doi: 10.1016/j.jtumed.2022.12.019. eCollection 2023 Aug. J Taibah Univ Med Sci. 2023. PMID: 36852237 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal